MGMT and neoplasm: Among these, patient age (4–10), functional status (4, 6–10), tumor location (8, 10–12), extent of resection (6, 7, 9, 10, 12), multifocality (5, 6), bilaterality (5, 7, 10), type of oncological treatment (5–7, 9–12), and the methylation status of the MGMT (6O-methylguanine-DNA methyltransferase) gene promoter (13, 14) are the strongest predictors for survival.